# Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia

Pau Montesinos,<sup>1</sup> June-Won Cheong,<sup>2</sup> Naval Daver,<sup>3</sup> Amir T. Fathi,<sup>4</sup> Mark J. Levis,<sup>5</sup> Selina Luger,<sup>6</sup> Toshihiro Miyamoto,<sup>7</sup> Esther N. Oliva,<sup>8</sup> Alexander E. Perl,<sup>6</sup> Christian Récher,<sup>9</sup> Richard Schlenk,<sup>10</sup> Jianxiang Wang,<sup>11</sup>

Amer M. Zeidan,<sup>12</sup> Li Liu,<sup>13</sup> Yvonne Duong,<sup>13</sup> Karima Imadalou,<sup>13</sup> Karenza Alexis,<sup>13</sup> Akash Nahar,<sup>13</sup> Kristy Burns,<sup>13</sup> Harry P. Erba<sup>14</sup>

¹Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain; ²Division of Hematology, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Massachusetts General Hospital, Seoul, Republic of Korea; ³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Massachusetts General Hospital Cancer Center, Boston, MA; ⁵Johns Hopkins University, Baltimore, MD; ⁶University of Pennsylvania, Philadelphia, PA; ⁴Department of Hematology, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa, Ishikawa, Japan; ⁶U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio di Calabria, Italy; ⁶Service d'hématologie, Centre Hospital and German Cancer Research Center, Heidelberg, Germany; ¹¹State Key Laboratory of Experimental Hematology, National Clinical Research Center, Hoidelberg, Tianjin, China; ¹²Department of Internal Medicine, New Haven, CT; ¹³Daiichi Sankyo, Inc., Basking Ridge, NJ; ¹⁴Duke University Cancer Institute, Durham, NC

## **SUMMARY**

- Quizartinib is an oral, selective, type-II inhibitor of FMS-like tyrosine kinase 3 (FLT3), with potent binding affinity against wild-type (WT) FLT3, FLT3 internal tandem duplications (ITDs), and several FLT3 variants with point mutations within the kinase domain
- In the PETHEMA phase 2, placebo-controlled QUIWI trial, quizartinib significantly prolonged overall survival (OS) when used in combination with Induction/Consolidation chemotherapy and as monotherapy Maintenance in patients with newly diagnosed (ND), FLT3-ITD—negative acute myeloid leukemia (AML)
- FLT3 is overexpressed in the majority of AML cases independent of the presence of a FLT3 gene mutation, and quizartinib has shown clinical activity in FLT3-ITD—negative ND AML
- QuANTUM-Wild is a randomized, double-blind, placebo-controlled, phase 3 trial of quizartinib in combination with chemotherapy and as monotherapy maintenance, in patients with FLT3-ITD—negative ND AML
- Approximately 700 patients will be enrolled at sites in North America, South America, Europe, Asia, and Australia
- If you have a patient that could benefit from participation in QuANTUM-Wild, please contact Daiichi Sankyo for clinical trial information via email at CTRinfo@dsi.com

## BACKGROUND


- Approximately 75% of patients with AML do not have a FLT3-ITD mutation (FLT3-ITD—negative)<sup>1</sup>
- Patients with FLT3-WTAML receiving 7+3-based intensive chemotherapy have a poor prognosis and high relapse rates<sup>2</sup>
   To date, no adjuvant targeted therapies have demonstrated OS improvements in this setting
- Inhibition of FLT3 and other AML-associated kinases could improve standard chemotherapy outcomes for fit patients with FLT3-WT AML
- The randomized SORAML trial, which included < 60 years old patients with *FLT3*-ITD and *FLT3*-WT ND AML, showed that the addition of type II inhibitor sorafenib to 7+3 chemotherapy improved leukemia-free survival, but not OS<sup>3</sup>
- Quizartinib is approved in combination with chemotherapy for the treatment of FLT3-ITD-positive ND AML based on the phase 3, QuANTUM-First trial (NCT02668653), and has also demonstrated clinical activity in FLT3-ITD-negative AML<sup>4-6</sup>
- In a phase 1 trial (NCT00462761), quizartinib treatment as a single-agent led to responses in patients with FLT3-ITD and FLT3-WT relapsed/refractory AML<sup>5</sup>
- Preliminary results from the randomized, placebo-controlled, phase 2, QUIWI trial by the PETHEMA group showed that adding quizartinib to Induction and Consolidation chemotherapy, followed by up to 12 months of single-agent quizartinib Maintenance for patients achieving complete remission (CR) or CR with incomplete count recovery (CRi), was associated with significantly prolonged OS in patients with ND, FLT3-ITD—negative AML<sup>6</sup>
- QuANTUM-Wild is an ongoing, double-blind, randomized, placebo-controlled, phase 3 trial assessing the addition of quizartinib to standard intensive Induction and Consolidation chemotherapy, followed by single-agent quizartinib Maintenance, in patients with FLT3-ITD-negative ND AML

## **METHODS**

## **Study Design**

- QuANTUM-Wild (ClinicalTrials.gov NCT06578247; EU CT 2023-507936-20-00) is a phase 3, double-blind, randomized, placebo-controlled trial enrolling patients 18–70 years of age with FLT3-ITD-negative ND AML
- FLT3-ITD negativity is defined as a FLT3-ITD mutant-to-total variant allele frequency (VAF) of < 5% by central assessment using a validated FLT3 assay; patients with FLT3-tyrosine kinase domain (TKD) mutations were not excluded</li>
- Patients cannot have AML secondary to prior chemotherapy or radiotherapy for other neoplasms, or secondary to an antecedent myelodysplastic syndrome or myeloproliferative neoplasm
- Key eligibility criteria and study design elements are illustrated in Figure 1

## Figure 1. QuANTUM-Wild Trial Design



<sup>a</sup>Induction chemotherapy begins during screening. <sup>b</sup>Option of HiDAC-135 or -123 schedules. allo-HSCT, allogeneic hematopoietic stem cell transplant; AML, acute myeloid leukemia; C1D7, cycle 1, day 7; ECOG PS, Eastern Cooperative Oncology Group performance status; FLT3, fms-like tyrosine kinase 3; HiDAC, high-dose cytarabine; ITD, internal tandem duplication; LTFU, long-term follow-up; ND, newly diagnosed; R, randomization; SR, signal ratio; VAF, variant allelic frequency; WHO, World Health Organization.

- The trial comprises four consecutive phases: Induction, Consolidation, Maintenance, and Long-Term Follow-Up
- Eligible patients are randomized in a 2:2:1 ratio into three treatment arms, stratified by region, age, and risk status:
   Arm A: quizartinib in all phases of treatment, in combination with chemotherapy during the Induction and Consolidation phases, then as monotherapy in the Maintenance phase
- Arm B: placebo in all phases of treatment, in combination with chemotherapy during the Induction and Consolidation phases, then as
  monotherapy in the Maintenance phase
- Arm C: quizartinib in combination with chemotherapy in the Induction and Consolidation phases, followed by placebo monotherapy in the Maintenance phase

#### **Study Phases**

- In the Induction phase, patients will receive the standard "7+3" Induction chemotherapy regimen of continuous infusion of cytarabine on days 1–7 and an anthracycline (either daunorubicin [60 mg/m²/day] or idarubicin
- [12 mg/m²/day], at investigator's discretion) on days 1–3, followed by quizartinib/placebo (60 mg) on days 8–21
- A second Induction cycle of either "7+3" or "5+2" chemotherapy is allowed if bone marrow blast count is ≥ 5% after first Induction
- Patients who achieve CR or CRi during Induction will enter the Consolidation phase and receive up to 4 cycles of high-dose cytarabine (HiDAC-135 or HiDAC-123 schedule) followed by quizartinib/placebo (60 mg) once daily for 14 days in each cycle
- Patients may receive an allogeneic hematopoietic stem cell transplant (allo-HSCT) at the investigator's discretion after completing at least 1 cycle of HiDAC Consolidation
- After Consolidation with HiDAC ± allo-HSCT, eligible patients will enter the Maintenance phase and receive continuous single-agent quizartinib (60 mg) once daily or placebo for up to 36 cycles
- The Maintenance phase will continue until relapse, start of non-protocol-specified AML treatment, death, unacceptable toxicity, trial closure, or completion of 36 cycles, whichever occurs first
- The Long-Term Follow-Up phase begins upon completion of 36 cycles of quizartinib/placebo in the Maintenance phase or permanent discontinuation of quizartinib/placebo in any phase

#### **Endpoints and Statistical Considerations**

• Primary, secondary, and key exploratory endpoints are detailed in Table 1

# Table 1. QuANTUM-Wild Trial Endpoints

Endpoint	Description
Primary endpoint:	
OS, Arm A vs Arm B	Time from randomization until death
Secondary endpoints:	
EFS	Time from randomization until failure to achieve CR at the end of Induction, relapse after CR, or death
DOCR	Time from CR until relapse or death
RFS	For patients who achieve CR, time from randomization until relapse or death
CR rate	Proportion of patients who achieve CR by end of Induction
CR <sub>MRD(-)</sub> Safety	MRD negativity by NPM1, CBF, and FLT3-ITD <sup>a</sup> Incidence of TEAEs, serious TEAEs, AESIs, changes in vital signs, ECG, safety laboratory evaluations, and physical examinations
PK of quizartinib and its metabolite, AC886	Plasma concentrations at each time point and PK parameters (AUC $_{24h}$ , C $_{max}$ , C $_{min}$ , T $_{max}$ and accumulation ratio and parent/metabolite ratio)

**Key exploratory endpoints:** CRc rate and duration; CIR; PROs; biomarkers (assessments of associations of molecular alterations and gene expression profiles with clinical responses); other efficacy outcomes for Arm A vs Arm B and Arm A vs Arm C

<sup>a</sup>NPM1 and CBF MRD are assessed individually in patients with these mutations present at screening, and FLT3-ITD MRD is assessed in all patients.


AESI, adverse event of special interest; AUC<sub>24h</sub>, area under the concentration versus time curve from time 0 to 24 hours; CBF, core binding factor; CIR, cumulative incidence of relapse; C<sub>max</sub>, maximum plasma concentration; C<sub>min</sub>, minimum plasma concentration; CR, complete remission; CRc, composite CR (CR + CR with incomplete blood count recovery [CRi]); DOCR, duration of CR; ECG, electrocardiogram; EFS, event-free survival; FLT3, FMS-like tyrosine kinase 3; ITD, internal tandem duplication; MRD, measurable residual disease; NPM1, nucleophosmin 1; OS, overall survival; PK, pharmacokinetics; PROs, patient reported outcomes; RFS, relapse-free survival; TEAE, treatment-emergent adverse event; T<sub>max</sub>, time to C<sub>max</sub>.

- The primary endpoint is OS, defined as the time from randomization until death by any cause, between Arm A and Arm B
- Arm C, which lacks quizartinib maintenance therapy compared to Arm A, is included for descriptive evaluation of the impact of single-agent quizartinib during the Maintenance phase
- The planned sample size is ~700 patients, including ~280 patients each in Arms A and B, and ~140 patients in Arm C
- The trial is powered for the primary analysis of OS between Arm A and Arm B; the planned sample size provides ≥ 90% power to detect an OS hazard ratio of 0.68 at a two sided significance level of 0.05
- The primary OS analysis will be performed when 289 deaths have occurred between Arm A and Arm B, and ≥ 24 months have elapsed since the last patient was randomized
- An OS interim analysis (IA) will be performed when approximately 231 deaths (~80% of target) have occurred and ≥ 15 months have elapsed since the last patient was randomized
- The study may be stopped at the OS IA if the pre-specified superiority boundary is crossed

# Enrollment

- Trial enrollment is currently ongoing
- Approximately 260 sites are planned across North and South America, Europe, Asia, and Australia (Figure 2)

## Figure 2. QuANTUM-Wild Enrolling Countries



### **REFERENCES**

- 1. Jalte M, et al. Cureus 2023;15:e45765
- 2. Boissel N et al. *Leukemia* 2002;16:1699–1704.
- 3. Röllig C, et al. *Lancet Oncol* 2015;16:1691–1699.

4. Erba HP, et al. Lancet 2023;401:1571–1583.

- 5. Cortes JE, et al. *J Clin Oncol* 2013;31:3681–3687.
- 6. Montesinos P, et al. *Hemasphere* 2023;7(Suppl):e734771d.
- 7. Arber DA, et al. *Blood*. 2016;127:2391–2405

# **ACKNOWLEDGMENTS**

- The authors thank the patients, families, and caregivers for their participation, and the study staff for their contributions
- This study is sponsored by Daiichi Sankyo Co., Ltd.
- Editorial support was provided by Declan Grewcock of Excerpta Medica, funded by Daiichi Sankyo Co., Ltd, and in accordance with Good Publication Practice (GPP) guidelines

# **DISCLOSURES**

P.M.: Janssen - advisory board, research support, speakers bureau; Daiichi Sankyo, AbbVie, Servier - consultancy, advisory board, research support/funding, speakers bureau; Astellas - consultancy, advisory board, research support, speakers bureau; Jazz, Pfizer, Novartis - consultancy, research funding, speakers bureau; Kura Oncology - consultancy; Syndax, Glycomimetics - consultancy. J-W.C.: no conflicts to declare. N.D.: Pfizer, Astellas - consultancy, research funding; Glycomimetics, KITE, Novimmune - research funding; Jazz, Syndax, Celgene, Novartis, Menarini, Agios, Arog, Shattuck Labs - consultancy; FATE Therapeutics - consulting fees, research funding; Servier, Trillium, Genentech, Gilead, Daiichi Sankyo, BMS consultancy, research funding; Hanmi - research funding. A.T.F.: AstraZeneca, Foghorn, Blueprint Medicines, Kura, Trillium - honoraria; Kite, PureTech, Daiichi Sankyo, Pfizer, Rigel, Menarini Group, Forma, Gilead, Ispen, Remix, Orum, Takeda, Amgen, Autolus, EnClear, Ipsen, Mablytics, ImmunoGen, BMS/Celgene, Novartis, Astellas, MorphoSys - consultancy; AbbVie, Servier - consultancy, research funding; Genentech - honoraria; AbbVie, BMS/Celgene, Agios/Servier - research funding; Agios - ended employment in the past 24 months; BMS - consultancy, research funding. M.J.L.: Takeda, Novartis, Daiichi Sankyo, BMS, Astellas, AbbVie - Consultancy. S.L.: Daiichi Sankyo, Marker Therapeutics, AbbVie - advisory board; Novartis consultancy, advisory board; Takeda - research funding; Amgen - consultancy, advisory board; Astellas - consultancy. T.M.: AbbVie, Janssen, Astellas, Otsuka, Takeda - honoraria; Chugai - research funding; Kyowa Kirin - honoraria, research funding. E.N.O.: Amgen, Novartis, Alexion, Sobi, BMS consultancy, honoraria, speakers bureau; Daiichi Sankyo - consultancy, honoraria; Ryvu - consultancy, honoraria, patents & royalties; Halia Therapeutics patents & royalties; Grande Ospedale Metropolitano Bianchi Melacrino Morelli - current employment; Janssen - speakers bureau. A.E.P.: Genentech, Aptose Biosciences, ImmunoGen, BMS, Curis, Schrödinger - advisory board; Syndax - grant, research funding; advisory board, research funding; AbbVie consultancy, advisory board, grant, consulting fees, research funding; Daiichi Sankyo - consultancy, honoraria, advisory board, grant, consulting fees; Astellas - consultancy, honoraria, advisory board, grant, consulting fees, research funding; Rigel - advisory board; Foghorn - consultancy; Beat AML, LLC: DSMC member. C.R.: Servier - advisory board, travel support; Novartis - travel support; J&J, Boehringer, Amgen - advisory board; AbbVie: advisory board, travel support, research funding; IQVIA - research funding; Daiichi Sankyo, Astellas, BMS, Jazz - advisory board, research funding. R.F.S.: Roche, PharmaMar, Recordati - receipt of equipment, materials, drugs, medical writing, gifts or other services, research funding; AstraZeneca - receipt of equipment, materials, drugs, medical writing, gifts or other services, research funding, speakers bureau; BerGenBio - advisory board, receipt of equipment, materials, drugs, medical writing, gifts or other services; Boehringer Ingelheim - research funding; Pfizer - honoraria, advisory board, research funding, speakers bureau, receipt of equipment, materials, drugs, medical writing, gifts or other services; Novartis - honoraria, advisory board, speakers bureau; Jazz - advisory board; AbbVie - advisory board, receipt of equipment, materials, drugs, medical writing, gifts or other services, research funding; Daiichi Sankyo - consultancy, honoraria, advisory board, receipt of equipment, materials, drugs, medical writing, gifts or other services, research funding, speakers bureau. J.W.: AbbVie: advisory board. A.M.Z.: Syros, BMS/Celgene, Takeda, Otsuka, Geron, Novartis, Kura, Amgen, AbbVie - consultancy, honoraria, research funding; Astex, Shattuck Labs - research funding; Epizyme, Keros, Lava Therapeutics, Orum, Gilead, BioCryst, Medus, Genentech, Regeneron, Boehringer Ingelheim, Rigel, Kyowa Kirin, Pfizer, ALX Oncology, Servier, Sumitomo, Karyopharm, Faron, Syndax, Zentalis, Akeso Pharma Schroedinger, Hikma, Vinerx, Glycomimetics, Daiichi Sankyo, Chiesi, Agios, Janssen, Notable, Treadwell, Taiho, Astellas, BeiGene - consultancy, honoraria. L.L., Y.D., K.I.: Daiichi Sankyo - employment. K.A.: Daiichi Sankyo - employment; Affirmed Inc - employment ended in the past 24 months. A.K.: Daiichi Sankyo - employment.. K.B.: Daiichi Sankyo - employment, equity. H.P.E.: Daiichi Sankyo - honoraria.

